Dyne Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $398.3M | $281.4M | $210.8M | $142.8M | $121.3M | $45.2M | $11.0M |
| SG&A Expense | $69.9M | $62.5M | $31.4M | $28.2M | $28.7M | $13.4M | $2.8M |
| Operating Income | $-468.2M | $-343.9M | $-242.2M | $-171.0M | $-150.0M | $-58.6M | $-13.8M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | — | — | — | — |
| Net Income | $-446.2M | $-317.4M | $-235.9M | $-168.1M | $-149.3M | $-59.4M | $-14.9M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | $-3.47 | $-3.37 | $-3.95 | $-3.23 | $-2.93 | $-4.13 | $-6.08 |
| EPS (Diluted) | $-3.47 | $-3.37 | $-3.95 | $-3.23 | $-2.93 | $-4.13 | $-6.08 |
| Shares Outstanding (Basic) | 165.0M | 102.3M | 61.5M | 55.6M | 51.6M | 45.1M | 2.6M |
| Shares Outstanding (Diluted) | 165.0M | 102.3M | 61.5M | 55.6M | 51.6M | 45.1M | 2.6M |
| Dividends Per Share | — | — | — | — | — | — | — |